Abstract
A tetrazolium-based colorimetric assay (MTT) was first introduced by Mossman in 1983 to assess the potential of novel antitumour agents, and it has been used here to evaluate the cytotoxicity of several soluble synthetic polymers proposed as drug carriers. Polymers including poly-l-lysine (molecular weight 57 000) were incubated (up to 1 mg ml−1) with two human cell lines, hepatocellular carcinoma (HepG2) and lymphoblastoid leukaemia (CCRF), adherent and suspension cells, respectively. Tests were carried out in the presence and absence of serum proteins. The assay was first modified to optimize the colorimetric profiles produced by the cell lines following incubation with MTT, to increase both the test sensitivity and the reproducibility of the method. Polymer toxicity observed using the MTT test was compared with data obtained using other methods; [3H]thymidine or [3H]leucine incorporation and counting cell numbers. Poly-l-lysine was very toxic to both cell lines with approximate IC50-values of 60 and 30 µg ml−1 for HepG2 and CCRF, respectively, the values obtained being similar for each of the three different viability methods used. In the absence of serum proteins the toxicity of poly-l-lysine increased, the IC50-values falling to 25.5 µg ml−1 for the adherent and 0.8 µg ml−1 for the suspension cell line. Other polymers such as poly-l-proline, polyethylene glycol, dextran, polyvinylpyrrolidone and poly-l-glutamic acid were not cytotoxic (MTT assay), either in the presence or in the absence of serum proteins. The MTT assay is a useful technique for the primary and rapid evaluation of the cytotoxicity of soluble polymers.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
D. F. WILLIAMS (editor), “Progress in Biomedical Engineering, 4. Definitions in Biomaterials”. Proceedings of a Consensus Conference of the European Society for Biomaterials, Chester, England (3–5 March 1986) (Elsevier, Amsterdam, 1987).
R. DUNCAN,CRC Crit. Rev Therapeut. Drug Carrier Syst. 1 (1985) 281.
A. F. VON RECUM (editor), “Handbook of Biomaterials Evaluation. Scientific, Technical and Clinical Testing of Implant Materials” (Macmillan, New York, 1987).
R. DUNCANet al., “Evaluation of the biocompatibility of soluble synthetic polymers designed as drug carriers”. Abstract from the International symposium on Controlled Drug Release of Bioactive Materials, Basle, Switzerland (1988) p. 121.
M. BHAKOO, D. SGOURAS and R. DUNCAN, “Evaluation of the biocompatibility (haemocompatibility and cytotoxicity) of soluble synthetic polymers designed as drug carriers”. Abstract from the International Conference on Polymers in Medicine, Warsaw, Poland (1988) p. 124.
F. P. ALTMAN,Prog. Histochem. Cytochem. 9 (1977) 1.
T. MOSSMAN,J. Immunol. Meth. 65 (1983) 55.
F. DENIZOT and R. LANG, ibid.89 (1986) 271.
J. CARMICHAELet al., Cancer Res. 47 (1987) 936.
M. C. ALLEYet al., ibid.48 (1988) 589.
Y. MAEHARAet al., Oncology 45 (1988) 434.
W.-C. SHEN and H. J.-P. RYSER,Mol. Pharmacol. 16 (1979) 614.
J. P. REMON, R. DUNCAN and E. SCHACHT,J. Controlled Release 1 (1984) 47.
II. A. RAVIH, A. M. SELINGMAN and J. FINE,N. Engl. J. Med. 247 (1952) 921.
C.-J. C. JAKSONet al., Analyt. Biochem. 165 (1987) 114.
W. A. R. VAN HEESWIJKet al., J. Controlled Release 1 (1985) 301.
A. L. SCHWARTZet al., J. Biol. Chem. 256 (1981) 8878.
G. E. FOLEY,et al., Cancer 18 (1965) 522.
D. V. LINDLEY, in “Introduction to Probability and Statistics from a Bayesian viewpoint. Part I. Probability” (Cambridge University Press, Cambridge, 1965) p. 135.
G. J. FINLAY, W. R. WILSON and B. C. BAGULEY,Eur. J. Clin. Oncol. 22 (1986) 655.
R. DUNCAN, in “Drugs and the Pharmaceutical Sciences”, Vol. 29: “Controlled Drug Delivery. Fundamentals and Applications” edited by J. R. Robinson and V. H. L. Lee (Marcel Dekker, New York, 1987) p. 581.
L. W. SEYMOURet al., J. Biomed. Mater. Res. 21 (1987) 1341.
J. DROBNÍK and F. RYPAČEK,Adv. Polym. Sci. 57 (1984) 1.
D. S. BRESLOW,Pure Appl. Chem. 46 (1976) 103.
A. E. GAD, B. L. SILVER and G. D. EYTAN,Biochim. Biophys. Acta 690 (1982) 124.
L. J. ARNOLDet al., Proc. Natl. Acad. Sci. USA 76 (1979) 3246.
D. PAPAHADJOPOULOS, M. MOSCARELLO, E. H. EYLAR and T. ISAC,Biochim. Biophys. Acta 401 (1975) 317.
M. A. STAHMANN, in Proceedings of an International Symposium on Polyamino Acids, Polypeptides and Proteins, edited by M. A. Stahmann (University of Wisconsin Press, Madison, 1962) p 329.
W. HARTMANN and H.-J. GALLA,Biochim. Biophys. Acta 509 (1978) 474.
D. M. L. MORGAN, J. CLOVER and J. D. PEARSON,J. Cell Sci. 91 (1988) 231.
M. BHAKOO, A. TUBOKU-METZGER and R. DUNCAN,J. Mater. Sci.: Mater. Med. to be submitted.
M. BHAKOOet al., ibid. to be submitted.
L. A. McCORMICK, MSc thesis, University of Keele (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sgouras, D., Duncan, R. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use: 1 — Use of the tetrazolium-based colorimetric assay (MTT) as a preliminary screen for evaluation ofin vitro cytotoxicity. J Mater Sci: Mater Med 1, 61–68 (1990). https://doi.org/10.1007/BF00839070
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00839070